• Users Online: 572
  • Print this page
  • Email this page

Table of Contents
Year : 2021  |  Volume : 4  |  Issue : 4  |  Page : 787-788

Authors' reply to Gupta et al.

Departments of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

Date of Submission18-Nov-2021
Date of Decision23-Nov-2021
Date of Acceptance20-Dec-2021
Date of Web Publication29-Dec-2021

Correspondence Address:
Joydeep Ghosh
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/crst.crst_295_21

Rights and Permissions

How to cite this article:
Ghosh J, Ganguly S, Biswas B. Authors' reply to Gupta et al. Cancer Res Stat Treat 2021;4:787-8

How to cite this URL:
Ghosh J, Ganguly S, Biswas B. Authors' reply to Gupta et al. Cancer Res Stat Treat [serial online] 2021 [cited 2022 Aug 20];4:787-8. Available from: https://www.crstonline.com/text.asp?2021/4/4/787/334226

We would like to thank Gupta and Kapoor[1] for reading our article with interest and critically analyzing its various aspects.[2] We sincerely appreciate the efforts of the authors on this.

Regarding the first point raised by Gupta and Kapoor, we completely agree that the role of surgery in the treatment journey for gestational trophoblastic neoplasia (GTN) is minimal. Many patients undergo surgery outside, and as rightly pointed out by Gupta and Kapoor, this is still a very common practice in the community. Given the small size of our cohort, we extracted all the previous surgical details and found that none of the three patients who received chemotherapy outside had undergone surgery related to GTN. Hence, we declare with sufficient confidence that none of the patients underwent surgery outside before coming to our center. As we have mentioned in the article, none of the patients underwent surgery at our center. We would like to clarify that we did not mention any patients who were operated on outside and treated at our center subsequently.

Regarding beta human chorionic gonadotropin testing, we went back and discussed with our biochemistry chief, who was of the opinion that if the value lies within the linearity range, we do not need to dilute the sample. However, if it is outside that range, as suggested by the authors, it is routine practice to dilute the sample and confirm the results.

Since this was a retrospective study, we completely agree that we had problems in collecting accurate data on toxicity. However, we have mentioned all the toxicity details that were available from the medical records and reports of blood counts to the best of our capacity.

I hope the authors find our replies satisfactory. We shall be more than happy to clarify any further questions from the authors.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Gupta A, Kapoor A. Gestational trophoblastic neoplasia: A road less travelled. Cancer Res Stat Treat 2021;4:786-7.  Back to cited text no. 1
  [Full text]  
Ghosh J, Dey S, Mandal D, Ganguly S, Biswas B, Dabkara D, et al. Clinicopathological features and outcomes of choriocarcinoma: A retrospective analysis from an Indian tertiary cancer center. Cancer Res Stat Treat 2021;4:486-91.  Back to cited text no. 2
  [Full text]  


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded23    
    Comments [Add]    

Recommend this journal